Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia

Acta Haematologica
J KaedaJohn M Goldman

Abstract

For patients with chronic myeloid leukaemia, methods for monitoring response to treatment have changed considerably in recent years. In the 1980s, the principal approach was repeated examination of bone marrow metaphases for the presence of the Ph chromosome in patients treated by interferon-alpha (IFN-alpha) or allogeneic stem cell transplantation. The use of fluorescence in situ hybridisation (FISH) techniques to detect the BCR-ABL fusion gene in Ph-positive leukaemia cells increased the sensitivity of cytogenetic studies to some degree. In the last 10 years, the reverse-transcriptase polymerase chain reaction (RT-PCR) has proved extremely valuable for assessing and monitoring minimal residual disease in patients who achieve Ph negativity after treatment with IFN-alpha or with the new Abl tyrosine kinase inhibitor imatinib mesylate or after allogeneic stem cell transplantation (SCT). Results are consistent with the notion that the majority of long-term survivors after allogeneic SCT are probably 'cured'; for other patients monitored serially in complete cytogenetic remission, rising numbers of BCR-ABL transcripts detected by RT-PCR can indicate the need for further therapy.

Citations

Feb 3, 2007·Journal of Applied Genetics·Justyna JółkowskaMałgorzata Dawidowska
Jan 17, 2004·Experimental Hematology·John M Goldman
Apr 4, 2008·Nature Reviews. Cancer·Michael Savona, Moshe Talpaz
Jun 5, 2003·Seminars in Hematology·John M GoldmanJane F Apperley
Dec 17, 2009·Hematology·John M Goldman
Sep 19, 2003·Wiener klinische Wochenschrift·Christian SillaberPeter Valent
Dec 14, 2011·Clinical Lymphoma, Myeloma & Leukemia·Stacie HollowayHanna Jean Khoury
Apr 5, 2008·Pathologie-biologie·S MenifK Dellagi
Jan 15, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David Marin
Jul 23, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jamshid S KhorashadDavid Marin
Nov 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David MarinLetizia Foroni
Jun 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hugues de LavalladeDavid Marin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.